|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2002-5-14
|
|
pubmed:abstractText |
We have reported that gemcitabine and concurrent radiation is a promising therapy for patients with pancreatic cancer. We investigated whether the addition of cisplatin, which may increase the systemic efficacy of gemcitabine, would be synergistic with gemcitabine and/or radiation in human pancreatic cancer cell lines.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0360-3016
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
53
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
140-5
|
|
pubmed:dateRevised |
2010-3-23
|
|
pubmed:meshHeading |
pubmed-meshheading:12007952-Cisplatin,
pubmed-meshheading:12007952-Combined Modality Therapy,
pubmed-meshheading:12007952-Deoxycytidine,
pubmed-meshheading:12007952-Drug Screening Assays, Antitumor,
pubmed-meshheading:12007952-Drug Synergism,
pubmed-meshheading:12007952-Humans,
pubmed-meshheading:12007952-Pancreatic Neoplasms,
pubmed-meshheading:12007952-Radiation-Sensitizing Agents,
pubmed-meshheading:12007952-Tumor Cells, Cultured
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
Concurrent chemoradiotherapy with gemcitabine and cisplatin for pancreatic cancer: from the laboratory to the clinic.
|
|
pubmed:affiliation |
Department of Radiation Oncology, University of Michigan Medical Center, 1500 E. Medical Center Drive, Ann Arbor, MI 48109, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.
|
